Ken Griffin Cassava Sciences Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $3.77 Million - $13.8 Million	393,600 Added 395.18%	493,200 $14.5 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $431,015 - $911,239	34,900 Added 53.94%	99,600 $1.23 Million
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $1.63 Million - $2.33 Million	-88,400 Reduced 57.74%	64,700 $1.31 Million
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $1.15 Million - $2.73 Million	-90,600 Reduced 37.18%	153,100 $3.45 Million
Q3 2023 Nov 14, 2023	SELL	$16.64 - $25.32 $1.47 Million - $2.24 Million	-88,400 Reduced 26.62%	243,700 $4.06 Million
Q2 2023 Aug 14, 2023	SELL	$21.59 - $27.88 $4.39 Million - $5.67 Million	-203,300 Reduced 37.97%	332,100 $8.14 Million
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $1.14 Million - $1.77 Million	48,700 Added 10.01%	535,400 $12.9 Million
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $2.21 Million - $3.5 Million	-79,300 Reduced 14.01%	486,700 $14.4 Million
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $1.29 Million - $4.05 Million	-79,300 Reduced 12.29%	566,000 $23.7 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $93.8M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.